# Sunshine Biopharma Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Sunshine Biopharma Inc.). ## Overview Sunshine Biopharma Inc. is a U.S.-based pharmaceutical company organized around generic prescription drugs, over-the-counter supplements, and proprietary drug development. Through its Canadian subsidiaries, it markets and distributes a broad portfolio of medicines in Canada while also advancing early-stage oncology and antiviral candidates. ## Products & services • Generic prescription drugs in Canada • OTC supplements and nutraceuticals • In-licensed and cross-licensed drug dossiers • Distribution rights for third-party pharmaceuticals • Proprietary R&D programs in oncology and antivirals - **Generic prescription pharmaceuticals** (80%) — Branded and unbranded generic medicines sold in Canada through Nora Pharma. - **Distribution-based pharmaceutical products** (10%) — Products sold under distribution agreements where the company acts as distributor and earns a sales share or margin. - **OTC supplements** (5%) — Health supplements and nutraceutical products sold through Sunshine Biopharma Canada. - **Proprietary drug development** (5%) — Early-stage internal pipeline assets including K1.1 and SBFM-PL4. - Generic prescription drugs in Canada - OTC supplements and nutraceuticals - In-licensed and cross-licensed drug dossiers - Distribution rights for third-party pharmaceuticals - Proprietary R&D programs in oncology and antivirals ## Customers The company sells primarily into the Canadian pharmaceutical supply chain, with pharmacies and other drug purchasers buying generic prescription medicines for everyday therapeutic use. It also serves partners in distribution and licensing arrangements, where third-party manufacturers or rights holders use the company to commercialize products in Canada. Its pipeline programs are aimed at future patients and healthcare providers in oncology and antiviral indications. - **Canadian pharmacies** (primary) — Buy generic prescription drugs for dispensing to patients and rely on supply continuity and regulatory approval. - **Pharmaceutical distribution partners** (primary) — Provide product rights or supply arrangements that the company commercializes in Canada. - **Retail and pharmacy supplement buyers** (secondary) — Purchase OTC products such as Essential•9, Calcium-Vitamin D, L-Citrulline, and Taurine. - **Healthcare providers and patients in target indications** (emerging) — Represent the eventual end market for proprietary oncology and antiviral candidates. - Canadian pharmacies buying generic prescription medicines - Healthcare distributors sourcing everyday and specialty drugs - Third-party pharma partners using Canadian commercialization channels - Consumers of OTC supplements through retail and pharmacy channels - Future patients and clinicians targeted by proprietary pipeline assets ## Geography Sunshine Biopharma is headquartered in the United States but its commercial footprint is centered in Canada through Nora Pharma and Sunshine Biopharma Canada. The company’s disclosed operations emphasize the Canadian generic drug market, while its proprietary licensing and development activities have a broader international character. Geography matters because Canadian regulatory approvals, product dossiers, and distribution relationships are central to how the business monetizes its portfolio. - **Canada** (90%) — Primary commercial market for generic drugs and OTC products - **United States** (10%) — Corporate domicile and R&D/licensing base - Headquartered in the United States - Commercial operations concentrated in Canada - Nora Pharma sells generic drugs under Canadian approvals - Sunshine Biopharma Canada develops and sells OTC products - Global licensing and patent rights support broader expansion ## Strategy The company’s strategy is to expand its Canadian generic-drug portfolio through in-licensing, cross-licensing, and distribution agreements while adding OTC products under its own authorizations. It also seeks to build a proprietary pipeline in oncology and antivirals, giving the business a longer-dated source of value beyond the commercial generic portfolio. Regulatory approvals, dossier ownership, and product breadth are central to its plan to deepen pharmacy access and broaden its product mix. - **Expand Canadian product breadth** (short-term) — A wider portfolio improves pharmacy access and strengthens the company’s position with buyers. - **Build proprietary pipeline value** (medium-term) — Internal drug candidates can create differentiated long-term upside beyond generic distribution. - **Increase commercialization efficiency** (short-term) — Better sourcing and product mix can improve the economics of the distributor model. - Expand the Canadian generic portfolio through licensing and supply agreements - Use distribution rights to add products without full internal development - Grow OTC offerings under company-owned Health Canada authorizations - Advance K1.1 and SBFM-PL4 in early-stage development - Broaden pharmacy access with a larger everyday and specialty medicine lineup ## Risks The business depends on regulatory approvals, product dossier execution, and third-party supply arrangements, which can delay launches or limit commercialization. It also faces typical pharmaceutical risks such as pricing pressure in generics, product concentration, and development risk in early-stage pipeline assets. Intangible asset impairment and the need for additional capital are important company-specific risks because they can affect reported results and funding flexibility. - **Regulatory approval and dossier execution risk** [high] — Products must be approved by Health Canada before commercialization, which can delay launches. - **Third-party supply and licensing dependence** [high] — Many products are sourced through in-licenses, cross-licenses, or distribution agreements. - **Intangible asset impairment** [high] — Product licenses may not be commercializable, requiring write-downs. - **Pipeline development failure** [medium] — K1.1 and SBFM-PL4 are early-stage and may not reach commercialization. - **Financing dependence** [high] — R&D and expansion can require external funding if operating cash is insufficient. - Health Canada approval timing can delay launches and revenue realization - Generic drug pricing and procurement pressure can compress economics - Third-party supply and licensing dependence can disrupt product availability - Early-stage pipeline assets may fail in development or never commercialize - Intangible asset impairments can reduce reported earnings and asset values - Additional capital may be needed for R&D and expansion ## Accounting Revenue recognition is important because the company sells through distribution agreements and licensed product arrangements, which can affect when sales are recorded and how gross margin is presented. Intangible asset valuation is a key judgment area because product licenses and rights can be impaired if commercialization prospects weaken. Investors should also watch estimates tied to inventory, product rights, and development-stage assets, since these can materially affect reported earnings and balance-sheet values. - **Revenue recognition on distribution agreements** — Can change gross revenue, net revenue, and margin presentation - **Intangible asset impairment** — Can materially reduce earnings and asset carrying values - **Inventory and cost of finished products** — Affects gross margin and quarter-to-quarter comparability - **Capitalized product rights and licenses** — Can influence amortization and impairment charges - Revenue timing under distribution and supply agreements - Gross margin sensitivity to product mix and procurement costs - Intangible asset impairment for product licenses and rights - Valuation of early-stage R&D assets and related estimates - Inventory and finished-product cost assumptions --- *Last updated: 2026-04-29T05:00:51.722702+00:00*